Biomedical Sciences, Fernand-Seguin Research Centre, Hôpital Louis-H. Lafontaine, Unit 218, 7401 Hochelaga, Montréal, Québec, Canada H1N 3M5.
Schizophr Res. 2010 Aug;121(1-3):266-70. doi: 10.1016/j.schres.2010.04.003. Epub 2010 May 8.
Non-compliance with pharmacotherapy among persons suffering from schizophrenia disorders stands at an average rate of 42% and is the subject of numerous studies. However, no studies to date have addressed the specific question of non-compliance with psychosocial treatment. The present study therefore aimed to determine the rate of drop-out from psychosocial treatment and to assess the influence of factors on this rate.
A meta-analysis was conducted based on 74 studies of randomized clinical trials on psychosocial treatment among persons suffering from schizophrenia spectrum disorder.
A drop-out rate of 13% was obtained. Age, gender, duration of illness, duration of treatment, treatment setting and study quality affected drop-out rates.
The 13% rate of drop-out from psychosocial treatment is markedly lower than the drop-out rate from pharmacotherapy studies. This finding supports the feasibility of evidence-based psychosocial treatment - which has, moreover, clearly been shown to be clinically effective - as part of a complete care program for schizophrenia.
精神分裂症患者药物治疗的不依从率平均为 42%，这是许多研究的主题。然而，迄今为止，尚无研究解决心理社会治疗不依从的具体问题。因此，本研究旨在确定心理社会治疗的脱落率，并评估这些因素对脱落率的影响。
对 74 项精神分裂症谱系障碍患者心理社会治疗的随机临床试验进行了荟萃分析。
脱落率为 13%。年龄、性别、病程、治疗时间、治疗环境和研究质量均影响脱落率。
心理社会治疗的 13%脱落率明显低于药物治疗研究的脱落率。这一发现支持将循证心理社会治疗作为精神分裂症综合治疗方案的一部分的可行性，因为这种治疗已被明确证明具有临床疗效。
